Abstracts tagged "tuberculosis and tumor necrosis factor (TNF)"

Abstract Number: 1252 • 2018 ACR/ARHP Annual Meeting
Screening for Tuberculosis before Initiating TNF Inhibitors: How Well Do We Do? a Nationwide Experience
Karim Ladak¹, Ting Pan² and Catherine MacLean¹, ¹Rheumatology, Hospital For Special Surgery, New York, NY, ²Value Office, Hospital For Special Surgery, New York, NY
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) revolutionized treatment of various conditions, however they drastically increase the risk of latent tuberculosis (LTBI) reactivation. Many national medical…
Abstract Number: 1225 • 2018 ACR/ARHP Annual Meeting
Screening for Acquired Latent Tuberculosis in Patients with Rheumatoid Arthritis(RA) on Anti-Tnfα Therapy (TNF-I) in Southern California
Noopur Goel¹, Karina Torralba², Lorena Salto¹ and Christina Downey³, ¹Loma Linda University, Loma Linda, CA, ²Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, ³Loma Linda University Medical Center, Loma Linda, CA
Background/Purpose: There is increased risk of tuberculosis in patients treated with TNF-I. ACR guidelines recommend annual screening for latent tuberculosis infection(LTBI) in RA patients with…
Abstract Number: 1234 • 2018 ACR/ARHP Annual Meeting
Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors
Hung Trinh and Darren Tabechian, Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are used to reduce the inflammatory process in many autoimmune diseases. Due to the risk of reactivation of…
Abstract Number: 2598 • 2016 ACR/ARHP Annual Meeting
Conversion Rate of Tuberculosis Screening Tests in Patients with Rheumatic Diseases While Receiving Anti-Tumor Necrosis Factor Alpha (anti-TNFα) Agents
Syed Hasan Raza¹, Syed Islam², Amado Freire³, Debendra Pattanaik⁴ and John Stuart⁵, ¹Rheumatology, University of Tennessee Health Science Center, Memphis, TN, ²University of Tennessee Health Science Center, Memphis, TN, ³Pulmonology - Critical Care, University of Tennessee Health Science Center, Memphis, TN, ⁴Rheumatology, University of TN Health Science Center, Memphis, TN, ⁵Medicine, VA Medical Center, University of Tennessee Health Science Center, Memphis, TN
Background/Purpose: Risk of opportunistic infections, particularly mycobacterial infections, is increased among patients with rheumatic diseases treated with anti-TNF α agents. Therefore, screening of patients for…
Abstract Number: 1352 • 2015 ACR/ARHP Annual Meeting
How Frequently Does Tuberculosis Screening Test Become Positive in Rheumatic Patients Treated with ANTI-Tumor Necrosis Factor-ALPHA Therapy? an Analysis of Risk Factors
Jorge Gaspar Ramos¹, Dafhne Miranda², Pilar Cruz-Dominguez³, Luis Javier Jara⁴ and Miguel A. Saavedra⁵, ¹Rheumatology, Hospital de Especialidades, Dr. Antonio Fraga Mouret, Centro Medico Nacional La Raza, IMSS, Mexico City, Mexico, ²Rheumatology, Rheumatology Unit, Hospital de Especialidades. Centro Médico La Raza, IMSS, Distrito federal, Mexico, ³Centro Médico Nacional La Raza IMSS, México, Mexico, ⁴Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁵Reumatología, Centro Médico Nacional La Raza IMSS, México DF., México D.F., Mexico
Background/Purpose: Anti-tumor necrosis factor-α (TNF-α) therapy is associated with an increased risk of mycobacterium tuberculosis infection. Tuberculosis (TB) reactivation can lead to severe complications in…
Abstract Number: 2810 • 2013 ACR/ARHP Annual Meeting
Follow-Up Testing Of Interferon-Gamma Release Assays For The Diagnosis Of Hidden Tuberculosis Infection In Patients Receiving Tumor Necrosis Factor Alpha Antagonists
Chan-Nam Son¹, Tae-Hwan Kim², Il-Hoon Sung³, Jae-Bum Jun² and Dae-Hyun Yoo², ¹Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Orthopaedic surgery, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Anti-tumor necrosis factor alpha (Anti-TNFα) therapy is often used in patients with rheumatic diseases who do not respond to conventional treatment. Risk of tuberculosis…
Abstract Number: 1521 • 2013 ACR/ARHP Annual Meeting
Latent Tuberculosis Screening and Treatment In Ankylosing Spondylitis Patients Eligible For Anti-TNF Therapy In Endemic Area
Renata Miossi¹, Karina Rossi Bonfiglioli¹, Carla G.S. Saad², Ana Cristina Ribeiro¹, Julio C. B. Moraes² and Eloisa Bonfá¹, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Anti-TNF agents have emerged as an important treatment for rheumatic diseases, particularly for ankylosing spondylitis (AS). Screening and treatment of latent tuberculosis infection (LTBI)…
Abstract Number: 1371 • 2013 ACR/ARHP Annual Meeting
Tuberculosis Infection In Patients With Tumor Necrosis Factor–α Antagonists In South Korea;retrospective Analysis Using By National Health Insurance Review and Assessment Service
Jong Wook Beom¹, Eun-Jung Park², Jinseok Kim³, Se Chang Park⁴ and Gi Hyeon Seo⁵, ¹Medicine, Jeju National University Hospital, Jeju, South Korea, ²Internal Medicine, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Republic of Korea, Jeju, South Korea, ³Internal Medicine, Jeju National University Hospital, Jeju, South Korea, ⁴Veterinary Medicine, Seoul National University, Seoul, South Korea, ⁵Health Insurance Review and Assessment Service, Seoul, South Korea
Background/Purpose: Tumor necrosis factor-α (TNF-α) antagonists bring new hope for treating rheumatoid arthritis (RA) over the past decade. However, the subsequent increased risk of developing…
Abstract Number: 1372 • 2013 ACR/ARHP Annual Meeting
Do We Really Identify Latent Tuberculosis? Comparison Of The Performance Of Tuberculin Skin Test and Interferon Gamma Release Assay Before Biologics: A Systematic Review and Meta-Analysis
Marie Locci¹, Françoise Barchechath-Flaisler², Jean-Louis Leroux¹ and Cécile Gaujoux-Viala³, ¹Nîmes University Hospital, Rheumatology Department, Nîmes, France, ²Nîmes University Hospital, Rheumatology Department, Nimes, France, ³EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France
Background/Purpose: Current guidelines mandate screening for latent tuberculosis infection prior to commencing anti-tumor necrosis factor therapy. However, many patients are already taking immunosuppressive therapy, which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].